Roche Announced That The European Commission (Ec) Has Approved Xofluza (Baloxavir Marboxil) In Children Aged One Year And Above For The Treatment Of Uncomplicated Influenza And For Post-Exposure Prophylaxis Of Influenza. Post-Exposure Prophylaxis Aims To Prevent Influenza In Individuals Following Contact With Someone Infected With The Influenza Virus. The Commission
